- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07531719
Un estudio de Risdiplam en participantes con atrofia muscular espinal (AME) tipo I y tipo II
Un estudio no intervencionista y multicéntrico que investiga los resultados del risdiplam en pacientes con atrofia muscular espinal de tipo I y tipo II
This multicenter, non-interventional, prospective study with a retrospective component aims to evaluate the real-world clinical outcomes, safety profile, and motor function improvements of Risdiplam treatment in participants with Type I and Type II Spinal Muscle Atrophy over 24 months of treatment.
The study will allow retrospective collection of medical history data and previous participants visits from the medical records.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Copia de seguridad de contactos de estudio
- Nombre: Reference Study ID Number: ML45655 https://forpatients.roche.com/ No attachments to email below.
- Número de teléfono: 888-662-6728 (U.S. Only)
- Correo electrónico: global-roche-genentech-trials@gene.com
Ubicaciones de estudio
-
-
-
Cairo, Egipto, 11566
- Reclutamiento
- Neurology Department, Ain Shams University Hospitals
-
Cairo, Egipto, DUMMY_VALUE
- Reclutamiento
- Air Force Specialized Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The participants must have a confirmed diagnosis of 5q-autosomal recessive SMA type I or type II with at least two survival motor neuron 2 (SMN2) copies for which Risdiplam is prescribed as per the SmPC.
Descripción
Inclusion Criteria:
- Maximum age to be 6 months for type I participants and 5 years for type II participants at the time of diagnosis.
- Participants must start/have started treatment with Risdiplam within 6 months of diagnosis.
- Participant to be receiving adequate nutrition and hydration at index date, in the opinion of the Investigator.
- Participant to be adequately recovered from any acute illness at the time index date.
Exclusion Criteria:
- Participants not receiving treatment for disease with Risdiplam according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling.
- Participants not receiving the Roche studied medicinal product, but a biosimilar.
- Concomitant or previous administration in any investigational drug or device study.
- Concomitant or previous administration of approved treatment for SMA other than Risdiplam.
- Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases at index date.
- Participants requiring invasive ventilation or tracheostomy at index date.
- Participants requiring awake non-invasive ventilation due to respiratory insufficiency or with awake hypoxemia with or without ventilator support or with history of respiratory failure or severe pneumonia, and have not fully recovered their pulmonary function at the time of index date.
- Severe contractures of joints of lower limbs and upper limbs at the time of index date.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Risdiplam Observational Arm
Data will be collected before, during and after treatment from participants who receive risdiplam treatment according to standard of care and Summary of Product Characteristics (SmPC). Participant data will be collected only during routine clinical interactions, with no additional study visits mandated. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change From Index Date in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) Score at Month 12
Periodo de tiempo: Baseline, Month 12
|
CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by the World Health Organization (WHO). Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam. |
Baseline, Month 12
|
|
Change From Index Date in Hammersmith Functional Motor Scale Expanded (HFMSE) Score at Months 12
Periodo de tiempo: Baseline, Months 12
|
HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the gross motor function measure (GMFM) with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function. The index date (D1) is when the participant was administered the first dose of Risdiplam. |
Baseline, Months 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Supervivencia global a los 24 meses
Periodo de tiempo: A los 24 meses
|
A los 24 meses
|
|
|
Tiempo hasta la Pérdida de la Función de Deglución Evaluada por el Médico del Estudio
Periodo de tiempo: Hasta el mes 24
|
Hasta el mes 24
|
|
|
Change From Index Date in CHOP-INTEND Score at Month 24
Periodo de tiempo: Baseline, Month 24
|
CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam. |
Baseline, Month 24
|
|
Percentage of Participants with CHOP-INTEND Score Improvement ≥ 4 Points Compared to Index Date at Months 12 and 24
Periodo de tiempo: Baseline, Months 12 and 24
|
CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal-oriented items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. The index date (D1) is when the participant was administered the first dose of Risdiplam. |
Baseline, Months 12 and 24
|
|
Percentage of Participants with CHOP-INTEND Score ≥ 40 at Months 12 and 24
Periodo de tiempo: At Months 12 and 24
|
CHOP-INTEND assessment is performed for participants aged <2 years or aged >2 years who are not able to sit > 10 seconds as defined by WHO. Information regarding the 16 items in the CHOP-INTEND motor assessment are to be collected. It includes both active movements, spontaneous or goal orientated items and of reflexive movements. It assesses head, neck, and trunk as well as proximal and distal limb strength. The score ranges from 0-64, higher scores representing better motor function outcomes. |
At Months 12 and 24
|
|
Change From Baseline in HFMSE Score at Month 24
Periodo de tiempo: Baseline, Month 24
|
HFMSE assessment is performed for participants who are ≥ 2 years and are sitters or walkers. Items on the original HFMS were expanded to capture higher functioning in SMA patients using 13 relevant additional items adapted from the GMFM with their scoring adapted to a three-point scale as in the original HFMS. The score ranges between 0 - 66, a higher score indicates a higher level of function. Baseline visit correspond with the index date (D1) where the participant was administered the first dose of Risdiplam. |
Baseline, Month 24
|
|
Number of Participants who Require Ventilatory Assistance
Periodo de tiempo: Up to 2 years follow-up per participant
|
Invasive ventilation and non-invasive ventilation due to respiratory insufficiency. Participants on permanent ventilation and when using it as temporary respiratory support will be assessed. |
Up to 2 years follow-up per participant
|
|
Duration of Ventilation
Periodo de tiempo: Up to 2 years follow-up per participant
|
Number of hours spent per day of non-invasive or invasive ventilation. Duration for both permanent ventilation and when used as temporary respiratory support will be assessed. |
Up to 2 years follow-up per participant
|
|
Time Until Permanent Ventilation
Periodo de tiempo: Up to 2 years follow-up per participant
|
Time until permanent ventilation is defined as ≥ 16 hours of non-invasive ventilation per day or intubation for > 21 consecutive days in the absence of, or following the resolution of, an acute reversible event or tracheostomy. |
Up to 2 years follow-up per participant
|
|
Ventilation-free Survival
Periodo de tiempo: Up to 2 years follow-up per participant
|
Assessed by duration of time from a specified index date until the initiation of permanent ventilation. |
Up to 2 years follow-up per participant
|
|
Change From Baseline in Growth Pattern
Periodo de tiempo: Up to Month 24
|
Growth patterns will be compared to standardized growth charts. |
Up to Month 24
|
|
Number of Participants With Musculoskeletal Abnormalities
Periodo de tiempo: Up to Month 24
|
Musculoskeletal abnormalities include scoliosis, kyphosis or other deformities |
Up to Month 24
|
|
Bulbar Function as Assessed by the Study Physician Versus Baseline
Periodo de tiempo: Up to Month 24
|
Bulbar function measures the ability to feed orally, chew, and ability to swallow versus baseline data. It also assesses the speaking and crying functions of the participant. |
Up to Month 24
|
|
Number of Participants With Adverse Events (AE) Serious Adverse Events (SAE)
Periodo de tiempo: Up to 2 years follow-up per participant
|
Data for incidence, seriousness, severity, and relatedness of all AEs reported or documented in medical notes by physicians during the safety observation period will also be reported. |
Up to 2 years follow-up per participant
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Trials, Hoffmann-La Roche
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- ML45655
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .